Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Stage, ER Status Guide HER2 Therapy Selection in Breast Cancer

September 17th 2017

The sequencing of therapies for patients with HER2-positive breast cancer is largely driven by stage of disease and hormone receptor status.

Implementation Research Key to Solving Global Cancer Care Puzzle

September 16th 2017

Health investment is failing to match the challenge presented by a growing cancer burden in countries at all economic levels, enhancing the need for new approaches that help optimize the delivery of care.

Precision Medicine Moving Beyond HER2 in Breast Cancer

September 16th 2017

There is a significant transformation underway in the treatment of breast cancer as research advances and new laboratory techniques continue to shrink the so-called "undruggable genome."

Dr. Muss on Adjuvant Therapy for Elder Patients with Breast Cancer

September 16th 2017

Hyman B. Muss, MD, School of Medicine, University of North Carolina (UNC)-Chapel Hill, Breast Cancer, Geriatric Oncology Program, Mary Jones Hudson Distinguished Professorship in Geriatric Oncology, UNC Lineberger Comprehensive Cancer Center, UNC School of Medicine, 2017 Giant of Cancer Care in Supportive/Palliative/Geriatric Care, discusses adjuvant therapy for elderly patients with HER2-positive or triple-negative breast cancer (TNBC).

Ovarian Suppression Individualization Warranted in Breast Cancer

September 16th 2017

Patients have a hard time with artificially induced menopause and some research suggests it may have a negligible effect on the success of their treatment.

Dr. O'Regan on Treatment of Breast Cancer in Premenopausal Women

September 16th 2017

Ruth O’Regan, MD, division head of Hematology and Oncology in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health, discusses treatment for premenopausal patients with breast cancer.

Dr. Baselga on Biomarker Research for Breast Cancer

September 16th 2017

José Baselga, MD, PhD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses biomarker research for patients with breast cancer.

Dr. Anderson on the Unmet Need in Low- and Middle-Income Breast Cancer Care

September 16th 2017

Benjamin O. Anderson, MD, a surgical oncologist at the Seattle Cancer Care Alliance, discusses the biggest unmet need for patients with breast cancer in low- and middle-income countries.

Multigene Testing Adds Complexity to Decision Making Process

September 16th 2017

Multigene panel testing offers a new but often puzzling tool for breast cancer treatment, since the results are often difficult to interpret, both for relative risk and risk management.

IBM's Watson has Potential Partnership With Oncologists

September 16th 2017

Even with advancements in technology, the prospect of artificial intelligence treating patients with cancer still remains out of reach. At least, for now.

"Opioid Epidemic" Increases Challenge of Treating Cancer Pain

September 15th 2017

Extra vigilance, careful management, and an emphasis on empathy makes treating cancer pain more effective during an opioid addiction epidemic.

Dr. Symmans on the Staging System for Breast Cancer

September 15th 2017

William F. Symmans, MD, professor of Pathology, The University of Texas MD Anderson Cancer Center, discusses the staging system for patients with breast cancer.

Paice on Current Pain Management for Breast Cancer

September 15th 2017

Judith Paice, PhD, RN, director of the Cancer Pain Program, Division of Hematology-Oncology, and research professor of Medicine, Northwestern University, discusses the pain management for patients with breast cancer.

Abemaciclib Improves PFS for HR+/HER2- Advanced Breast Cancer

September 10th 2017

The addition of abemaciclib to anastrozole or letrozole reduced the risk of progression or death by 46% compared with the non-steroidal aromatase inhibitors alone for previously untreated patients with HER2-negative, HR-positive advanced breast cancer.

Immune System Priming Prior to Checkpoint Blockade Improves Response in Metastatic TNBC

September 9th 2017

Turning a nonimmunogenic (“cold”) tumor into an immunogenic (“hot”) tumor appears feasible in patients with metastatic triple negative breast cancer, thereby improving sensitivity to immune therapy with nivolumab.

Dr. Esteva on Next-Generation Sequencing in Metastatic Breast Cancer

September 8th 2017

Francisco J. Esteva, MD, PhD, medical oncologist, NYU Langone Medical Center, discusses next-generation sequencing in metastatic breast cancer.

Taselisib, Letrozole Combination Active for ER+, HER2- Early Breast Cancer

September 8th 2017

Taselisib added to standard letrozole (Femara) improved the objective response rate compared to letrozole with a placebo in postmenopausal women with estrogen receptor-positive and HER2-negative early breast cancer.

Dr. Tolaney Discusses Pertuzumab in HER2+ Breast Cancer

September 8th 2017

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses pertuzumab (Perjeta) in patients with HER2-positive breast cancer.

Dr. Tolaney on the Current Treatment Landscape for HER2+ Breast Cancer

September 7th 2017

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the current treatment landscape for patients with HER2-positive breast cancer.

Z-endoxifen Shows Promise in Endocrine Refractory Breast Cancer

September 5th 2017

Z-endoxifen, a potent derivative of the drug tamoxifen, induced tumor shrinkage in women with ER-positive metastatic breast cancer who had progressed on standard anti-estrogen therapies.